Cyndi Shannon Weickertprofile image
Professor

Cyndi Shannon Weickert


Current Appointments

NSW Chair of Schizophrenia Research
Professor, School of Psychiatry, UNSW Professor, Department of Neuroscience and Physiology, Upstate Medical University, New York
email hidden; JavaScript is required

Cyndi’s research is focused on the molecular developmental neurobiology of schizophrenia. She earned a PhD in Biomedical Science at Mount Sinai School of Medicine, New York City and completed postdoctoral training at the National Institute of Mental Health rising to the level of Unit Chief of Molecules in the Neurobiology and Development of Schizophrenia Unit. Her awards include the Eli Lilly Young Investigator Award, NIH Fellows Award for Research Excellence, Independent Investigator Award and two Young Investigator Awards from NARSD. She has lectured throughout the world and contributed to over 150 publications.

My research has several aims:

  • To determine the neurobiological underpinning of psychiatric diseases in order to develop more effective treatments.
  • To identify biological subgroups of people with schizophrenia based on inflammation.  To determine if these subgroups cut across schizophrenia, bipolar and depression.
  • To use knowledge gained on neuroinflammation subgroups in major psychiatric disorders to inform the development of biologically informed treatments (or more individualised treatments).
  • To understand how the balance between factors that damage brain cells verses factors that repair and regenerate brain cells differ in psychiatric conditions.

Publications

2024 Oct

Molecular Evidence for Altered Angiogenesis in Neuroinflammation-Associated Schizophrenia and Bipolar Disorder Implicate an Abnormal Midbrain Blood-Brain Barrier.

View full journal-article on http://europepmc.org/abstract/med/39471484

2024 Oct

Schizophrenia-associated changes in neuronal subpopulations in the human midbrain.

View full journal-article on http://europepmc.org/abstract/med/39397771

2024 Sep

Transcriptional evidence of reduced BDNF trophic signalling capacity in the post-mortem human midbrain of schizophrenia cases with high inflammation

View full preprint on http://europepmc.org/abstract/PPR/PPR905530

2024 Aug

Increased Parenchymal Macrophages are associated with decreased Tyrosine Hydroxylase mRNA levels in the Substantia Nigra of people with Schizophrenia and Bipolar Disorder.

View full journal-article on http://europepmc.org/abstract/med/39153291

2024 Jul

Antipsychotic-induced prolactin elevation in premenopausal women with schizophrenia: associations with estrogen, disease severity and cognition.

View full journal-article on http://europepmc.org/abstract/med/38995314

2024 Jul

Molecular evidence of altered stress responsivity related to neuroinflammation in the schizophrenia midbrain.

View full journal-article on http://europepmc.org/abstract/med/39004003

2024 Jun

The association of prolactin and gonadal hormones with cognition and symptoms in men with schizophrenia spectrum disorder: Divergent effects of testosterone and estrogen.

View full journal-article on http://europepmc.org/abstract/med/38944973

2024 May

RNA-sequencing suggests extracellular matrix and vasculature dysregulation could impair neurogenesis in schizophrenia cases with elevated inflammation.

View full journal-article on http://europepmc.org/abstract/med/38704390

2024 Mar

Single-Nucleus RNA-Seq Characterizes the Cell Types Along the Neuronal Lineage in the Adult Human Subependymal Zone and Reveals Reduced Oligodendrocyte Progenitor Abundance with Age.

View full journal-article on http://europepmc.org/abstract/med/38351133

2024 Mar

Toll-Like Receptor mRNA Levels in Schizophrenia: Association With Complement Factors and Cingulate Gyrus Cortical Thinning.

View full journal-article on http://europepmc.org/abstract/med/38102721